Stocktoria
NovoCure Ltd NVCR
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2015-10-01
NovoCure Ltd statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% |
| Operating margin | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% |
| Net margin | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% |
| FCF margin | -11.5% | -11.4% | -19.7% | 1.8% | 11.0% |
| Return on assets | -16.9% | -13.6% | -18.1% | -7.8% | -5.1% |
| Return on equity | -40.0% | -46.8% | -57.1% | -21.0% | -14.2% |
| Debt / equity | 0.57× | 0.27× | 1.57× | 1.28× | 1.37× |
| Current ratio | 2.90 | 1.46 | 5.78 | 7.00 | 7.53 |
| Revenue growth | 8.3% | 18.8% | -5.3% | 0.5% | 8.2% |
Source: SEC EDGAR filings · CIK 0001645113 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.